| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
CRY1 (cryptochrome 1). KL044 stabilizes the CRY1 protein and prolongs the circadian period. CRY1 is a core component of the circadian clock that represses CLOCK-BMAL1-mediated transcription.
|
|---|---|
| ln Vitro |
In the HEK293 stable cell line, KL044 (0-3.7 μM; 8 h) efficiently stabilizes the CRY1-LUC fusion protein without compromising the stability of LUC [1].
KL044 effectively stabilizes the CRY1-LUC fusion protein without affecting the stability of LUC in HEK293 stable cell lines (0-3.7 µM; 8 h). It has a pEC50 value of 7.32. KL044 prolongs the circadian period and represses Per2 activity. It inhibits melanogenesis through suppression of the cAMP/PKA/CREB pathway. |
| ln Vivo |
No detailed in vivo activity data has been published in the available literature. KL044 is primarily characterized as an in vitro chemical probe for studying circadian rhythm and CRY1 function. Further in vivo studies in animal models of circadian rhythm disorders would be needed to evaluate its effects.
|
| Enzyme Assay |
CRY1-LUC stabilization assay: HEK293 stable cell lines expressing CRY1-LUC fusion protein are treated with KL044 at varying concentrations (0-3.7 µM) for 8 hours. Luciferase activity is measured using a luciferase assay system. The stabilization of CRY1-LUC protein is assessed by comparing luciferase signal to untreated controls. pEC50 values are calculated from dose-response curves.
|
| Cell Assay |
Circadian rhythm assay: Cells expressing circadian reporter genes (e.g., Bmal1-LUC or Per2-LUC) are synchronized with dexamethasone and treated with KL044. Luminescence is recorded in real-time over several days using a luminometer. Circadian period length and amplitude are calculated from the luminescence rhythm. Repression of Per2 activity is assessed.
|
| Animal Protocol |
No in vivo animal experimental protocols have been published for KL044 in the available literature. In vivo studies would typically involve mouse models of circadian rhythm disruption, where KL044 would be administered via appropriate routes, followed by measurement of behavioral circadian rhythms (e.g., wheel-running activity), clock gene expression in tissues, and metabolic parameters.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data has been published in the available literature. KL044 has a molecular formula C₂₁H₁₄ClN₃O and purity >98%. Comprehensive PK parameters such as bioavailability, half-life, and plasma protein binding remain to be characterized.
|
| Toxicity/Toxicokinetics |
No toxicity data has been published in the available literature. KL044 is for research use only. Standard laboratory safety practices should be followed when handling this compound. As a modulator of circadian rhythm, potential effects on sleep-wake cycles and metabolism should be considered.
|
| References | |
| Additional Infomation |
Stable cryptochrome protein; structure can be found in the first article.
KL044 is a potent CRY1 stabilizer with a pEC50 of 7.32. It prolongs the circadian period and represses Per2 activity. KL044 inhibits melanogenesis through suppression of the cAMP/PKA/CREB pathway. It is a valuable chemical probe for studying circadian biology and clock protein function. No clinical trials or approved上市 status have been reported. |
| Molecular Formula |
C21H14CLN3O
|
|---|---|
| Molecular Weight |
359.81
|
| Exact Mass |
359.082
|
| CAS # |
1801856-93-8
|
| PubChem CID |
91827381
|
| Appearance |
Off-white to gray solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
567.6±60.0 °C at 760 mmHg
|
| Flash Point |
297.1±32.9 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.675
|
| LogP |
6.46
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
551
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C3=CC=CC=C3N2CC(=O)NC4=C(C=CC=C4Cl)C#N
|
| InChi Key |
ZDAKKNHUWVTCRS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H14ClN3O/c22-17-9-5-6-14(12-23)21(17)24-20(26)13-25-18-10-3-1-7-15(18)16-8-2-4-11-19(16)25/h1-11H,13H2,(H,24,26)
|
| Chemical Name |
2-carbazol-9-yl-N-(2-chloro-6-cyanophenyl)acetamide
|
| Synonyms |
KL-044; KL 044; KL044
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~277.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7792 mL | 13.8962 mL | 27.7924 mL | |
| 5 mM | 0.5558 mL | 2.7792 mL | 5.5585 mL | |
| 10 mM | 0.2779 mL | 1.3896 mL | 2.7792 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
